Search

Issue Volume 2:Issue 12(2015)

31. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Issue 12 (December 2015)

Authors:
Imagawa, Jun; Tanaka, Hideo; Okada, Masaya; Nakamae, Hirohisa; Hino, Masayuki; Murai, Kazunori; Ishida, Yoji; Kumagai, Takashi; Sato, Seiichi; Ohashi, Kazuteru; Sakamaki, Hisashi; Wakita, Hisashi; Uoshima, Nobuhiko; Nakagawa, Yasunori; Minami, Yosuke; Ogasawara, Masahiro; Takeoka, Tomoharu; Akasa...
Journal:
Lancet
Issue:
Volume 2:Issue 12(2015)
Page Start:
e528
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Issue 12 (December 2015)

Authors:
Richardson, Paul G; Jagannath, Sundar; Moreau, Philippe; Jakubowiak, Andrzej J; Raab, Marc S; Facon, Thierry; Vij, Ravi; White, Darrell; Reece, Donna E; Benboubker, Lotfi; Zonder, Jeffrey; Tsao, L Claire; Anderson, Kenneth C; Bleickardt, Eric; Singhal, Anil K; Lonial, Sagar
Journal:
Lancet
Issue:
Volume 2:Issue 12(2015)
Page Start:
e516
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search